The British Business Bank is a government-owned financial institution operating economic development initiatives and investment programmes for smaller businesses.
The London-based startup has secured pre-seed funding from Haatch Ventures and the British Business Bank to expand its team and defence operations.
"We spent years watching companies drown in their own data. The information was there, but getting to it meant waiting on overloaded engineering or data teams, with dozens of tasks ahead of yours! We started Dataline Labs because we believed there had to be a faster way – and now we’re proving it with a vote of confidence from investors and the MoD."
The round was led by Sofina with participation from Better Society Capital and existing investors.
"Stream exemplifies how placing impact considerations at the heart of product development can drive sustainable commercial value. Its focus on tackling the 'poverty premium' not only works to improve financial resilience, but also solve critical challenges for employers. Stream's dedication to understanding and improving their products' impact on users enables greater positive outcomes and propels their strong commercial growth, and we look forward to the impact this funding will support."
The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.
"Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process."
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
"Refractory epilepsy is a devastating condition causing unpredictable and life-threatening seizures, and affecting millions of patients worldwide. Our novel gene therapy EPY201 delivered directly to the seizure focus has the potential to stop seizures with a single, minimally invasive administration. In doing so, it will change the way refractory epilepsy has been treated for decades. We are proud to have the support of such high calibre investors as we progress into clinical trials."
